| [1] Mozaffarian D, Benjamin E J, Go A S, et al. Heart disease and stroke statistics—2016 update a report from the American Heart Association [J]. Circulation, 2016, 133(4): 447-545.
[2] Gheorghiade M, Pang P S. Acute heart failure syndromes [J]. J Am Coll Cardiol, 2009, 53(7): 557-573.
[3] Tilemann L, Ishikawa K, Weber T, et al. Gene therapy for heart failure [J]. Circ Res, 2012, 110(5): 777-793.
[4] Yerevanian A, Yerevanian A, Hajjar R J. Progress in gene therapy for heart failure [J]. J Cardiovasc Pharm, 2014, 63(2): 95-106.
[5] Gao M H, Lai N C, Miyanohara A, et al. Intravenous adeno-associated virus serotype 8 encoding urocortin-2 provides sustained augmentation of left ventricular function in mice [J].
Hum Gene Ther, 2013, 24(9): 777-785.
[6] Lai N C, Tang T, Gao M H, et al. Improved function of the failing rat heart by regulated expression of insulin-like growth factor Ⅰvia intramuscular gene transfer [J]. Hum Gene Ther,
2012, 23(3): 255-261.
[7] Ding Q R, Strong A, Patel K M, et al. Permanent alteration of PCSK9 with in vivo CRISPRCas9 genome editing [J]. Circ Res, 2014, 115(5): 488-492.
[8] Su C H, Wu Y J, Wang H H, et al. Nonviral gene therapy targeting cardiovascular system [J]. Am J Physiol Heart C, 2012, 303(6): H629-H638.
[9] Gyongyosi M, Khorsand A, Zamini S, et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia—subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study [J]. Circulation, 2005, 112(9): 1157-1165.
[10] Scimia M C, Cannavo A, KochWJ. Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium [J]. Expert Rev Cardiovasc Ther, 2013, 11(8): 999-1013.
[11] Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery [J]. Annu Rev Biomed Eng, 2007, 9: 415-447.
[12] Fujii H, Sun Z, Li S H, et al. Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice [J]. JACC Cardiovasc Imaging, 2009, 2(7): 869-879.
[13] Fujii H, Li S H, Wu J, et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair [J]. Eur Heart J, 2011, 32(16): 2075-2084.
[14] Gill S L, O’neill H, McCoy R J, et al. Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro
model [J]. Technol Health Care, 2014, 22(1): 37-51.
[15] Petrus I, Chuah M, Vandendriessche T. Gene therapy strategies for hemophilia: benefits versus risks [J]. J Gene Med, 2010, 12(10): 797-809.
[16] Kay M A. State-of-the-art gene-based therapies: the road ahead [J]. Nat Rev Genet, 2011, 12(5): 316-328.
[17] Schneider C K, Salmikangas P, Jilma B, et al. Challenges with advanced therapy medicinal products and how to meet them [J]. Nat Rev Drug Disc, 2010, 9(3): 195-201.
[18] Mingozzi F, High K A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy [J]. Blood, 2013, 122(1): 23-36.
[19] Wasala N B, Shin J H, Duan D S. The evolution of heart gene delivery vectors [J]. J Gene Med, 2011, 13(10): 557-565.
[20] Parker A L, Nicklin S A, Baker A H. Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications [J]. Curr Opin Mol Ther, 2008, 10(5):
439-448. |
